Most cited papers from Seagen (Canada)

Seagen (Canada)

What are the most cited papers from Seagen (Canada)?

The most cited paper from Seagen (Canada) is "Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study" (Barbara Pro, Ranjana H. Advani, Pauline Brice et al., 2012), with 1,001 citations. Next come "Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (785) and "Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels" (569).

Published TypeFieldAccessCitations

Showing 49 of 49 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology Open access	21 May 2012	1,001
2	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Laurie Helen Sehn, Alex Francisco Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology Open access	6 Nov 2019	785
3	Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels James N. Kochenderfer et al. · Journal of Clinical Oncology Open access	14 Mar 2017	569
4	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma Christopher James Gibson et al. · Journal of Clinical Oncology Open access	23 Feb 2017	483
5	The Effect of Garlic Supplements on the Pharmacokinetics of Saquinavir Stephen C. Piscitelli, Aaron H. Burstein, Nada Welden et al. · Clinical Infectious Diseases	15 Jan 2002	432
6	Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study Michelle C. Janelsins, Charles E. Heckler, Luke Joseph Peppone et al. · Journal of Clinical Oncology Open access	10 Feb 2017	399
7	Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia Xueyan Chen, Hu Xie, Brent Lee Wood et al. · Journal of Clinical Oncology Open access	3 Mar 2015	260
8	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis David R.W. Jayne, Brad H. Rovin, Eduardo Mysler et al. · Annals of the Rheumatic Diseases Open access	10 Feb 2022	204
9	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 + Peripheral T-Cell Lymphomas: Results of a Phase I Study Michelle A. Fanale, Steven M. Horwitz, Andres Forero‐Torres et al. · Journal of Clinical Oncology Open access	19 Aug 2014	179
10	A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy Curtis Cooper, Rolf P. G. van Heeswijk, Keith Gallicano et al. · Clinical Infectious Diseases	15 Jun 2003	161
11	Challenges and opportunities for conservation of forest genetic resources Om P. Rajora, Ale× Mosseler · Euphytica	Mar 2001	144
12	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy Chunkit Fung, Howard D. Sesso, AnnaLynn M. Williams et al. · Journal of Clinical Oncology Open access	27 Feb 2017	109
13	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study Nancy U. Lin, Mark Daniel Pegram, Solmaz Sahebjam et al. · Journal of Clinical Oncology Open access	4 May 2021	94
14	First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer Matthew Philip Goetz et al. · Journal of Clinical Oncology Open access	30 Aug 2017	82
15	Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia Peter D. Cole, Yaron Finkelstein, Kristen E. Stevenson et al. · Journal of Clinical Oncology Open access	19 May 2015	76
16	Paroxysmal Nocturnal Hemoglobinuria and Marrow Failure Treated by Infusion of Marrow from an Identical Twin A Fefer, H. FREEMAN, R. STORB et al. · Annals of Internal Medicine	Jun 1976	54
17	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR Stéphanie A. Blankenstein, Maartje W. Rohaan, W. Martin C. Klop et al. · Annals of Surgery Open access	9 Apr 2021	47
18	Multi-Site N-glycan mapping study 1: Capillary electrophoresis – laser induced fluorescence Ákos Szekrényes et al. · mAbs Open access	14 Oct 2015	43
19	Base alterations in yeast induced by alkylating agents with differing Swain-Scott substrate constants Grace S. -F. Lee, Karla S. Blonsky, Diane Lee Van On et al. · Journal of Molecular Biology	Feb 1992	41
20	Interconceptional Counseling After Perinatal and Infant Loss Cheryl Wallerstedt, Margaret Lilley, Kathleen A. Baldwin · Journal of Obstetric, Gynecologic & Neonatal Nursing	Jul 2003	35
21	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies Surinder Kaur et al. · Bioanalysis Open access	May 2022	31
22	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? Mark J. Levis, Yi‐Bin Chen, Mehdi Hamadani et al. · Journal of Clinical Oncology Open access	29 Apr 2019	31
23	Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer Karen L. Reckamp · Journal of the National Comprehensive Cancer Network Open access	May 2018	28
24	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors Samuel Aaron Funt, Sujata N Patil, Darren Richard Feldman et al. · Journal of Clinical Oncology Open access	25 Jun 2019	26
25	Maternal transmission of mitochondrial DNA in interspecific hybrids of Populus Om P. Rajora, John W. Barrett, Bruce P. Dancik et al. · Current Genetics Open access	Aug 1992	22
26	2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Report Johanna R. Mora et al. · Bioanalysis Open access	22 Feb 2024	21
27	Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma Rasmus Rask Kragh Jørgensen, Fanny Bergström, Sandra Eloranta et al. · JCO Clinical Cancer Informatics Open access	Apr 2024	15
28	Registration of Centennial Barley1 (Reg. No. 108) L. P. V. Johnson · Crop Science	May 1969	15
29	Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada Nimira S. Alimohamed, Simrun Kaur Grewal, Heidi S. Wirtz et al. · Current Oncology Open access	12 Oct 2022	11
30	Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials Rong Liu, Ying Yuan, Suman Sen et al. · Statistics in Biopharmaceutical Research Open access	23 May 2022	11
31	The eptinezumab:CGRP complex structure – the role of conformational changes in binding stabilization Laurent David, Michelle L. Scalley-Kim, Andrea M. Olland et al. · Bioengineered Open access	11 Dec 2021	10
32	Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events Kathleen Clifford, Amanda R. M. Copeland, Gregory Knutzen et al. · Clinical journal of oncology nursing	23 Jul 2018	8
33	Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie Andy Kahles, Hannah Goldschmid, Anna‐Lena Volckmar et al. · Die Pathologie Open access	4 Oct 2023	6
34	Commercial production of recombinant erythropoietins Alice S. Chuck, Adrian R. Distler, Shane A. Sander et al. · Birkhäuser Basel eBooks Book chapter	2009	5
35	In Defense of TNT: A Dynamite Strategy Andrea Cercek, Paul Bernard Romesser, Christopher H. Crane et al. · Journal of Clinical Oncology Open access	9 Feb 2021	4
36	The cell cycle variant in multiciliated cells incorporates 2 centriole biogenesis cycles Amélie-Rose Boudjema, Rémi Balagué, Cayla E Jewett et al. · eLife Open access	13 May 2024	3
37	Development of DHES0815A; a novel HER2-directed antibody-drug conjugate comprised of a reduced potency mono-alkylating agent linked to a domain I binding HER2 antibody Gail Lewis et al. · Research Square PreprintOpen access	21 Dec 2022	3
38	Functional Characterization of Cooperating MGA Mutations in RUNX1::RUNX1T1 Acute Myeloid Leukemia Jeffery M. Klco, Melvin Edward Thomas, Wenqing Qi et al. · Research Square PreprintOpen access	22 Sep 2023	2
39	POSSIBLE IMMUNOLOGICAL INFLUENCE ON SEX RATIO David L. Sackett, Krishna R. Dronamraju · The Lancet	Oct 1967	2
40	Microtubule-dependent orchestration of centriole amplification in brain multiciliated cells Amélie-Rose Boudjema, Rémi Balagué, Cayla E Jewett et al. · eLife Open access	13 May 2024	1
41	REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Alicia Katherine Morgans, Guru Sonpavde, Vanessa Shih et al. · Urologic Oncology Seminars and Original Investigations	Mar 2024	1
42	Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study Andrew M. Evens, Kristina S. Yu, Nicholas Liu et al. · Future Oncology Open access	4 Sep 2023	1
43	177TiP: Phase II clinical study of adebrelimab combined with carboplatin, albumin-bound paclitaxel, and recaticimab in perioperative treatment of resectable NSCLC Jianwei Wang, Yung-Fu Wu, Changjun Wang et al. · Journal of Thoracic Oncology Open access	Mar 2025	0
44	Predictors of brain metastases in patients with oligometastatic solid tumours treated with stereotactic body radiation therapy Kevin Yijun Fan, Katarzyna Joanna Jerzak, Sudhir Kumar et al. · Research Square PreprintOpen access	13 Aug 2024	0
45	Beyond the first line of HER2+ metastatic breast cancer Carmen Salvador Coloma · Revisiones en cáncer Open access	2023	0
46	P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial F. Cao, Z. Ma, G. Hu et al. · The Breast Open access	14 Mar 2023	0
47	MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers Kohei Shitara, Haeseong Park, Tanios Bekaii‐Saab et al. · Annals of Oncology Open access	Jul 2022	0
48	NURSING FORUM Gretchen J. Carrougher, Edward E. Tredget · Journal of Burn Care & Rehabilitation	Jul 2001	0
49	Vaccine targeting HIF1A in triple negative breast cancer Denise L. Cecil, Daniel R. Herendeen, Meredith Slota et al. · Journal for ImmunoTherapy of Cancer Open access	6 Nov 2014	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.